INSIGHTS ON CELL & GENE REGULATORY ISSUES

• All The Ways Global Biopharma Still Grapples With Annex 1

  Biopharma companies can't consistently meet Annex 1 expectations. At the heart of the problems, regulators have shifted the burden of proof to manufacturers.

• Integrated Quality, Regulatory, And Safety Services

  A single-vendor model for quality, regulatory, and safety services provides consistent project management and cost-effective scalability. Hear how integrated solutions support market entry and growth.

• Why Manufacturing Drives FDA CRLs In Cell Therapy

  Manufacturing and quality gaps drive most FDA Complete Response Letters in cell therapy, often stemming from early‑stage decisions and unresolved CMC issues that become major late‑stage approval risks.

• A Faster Path To Genomic Medicine Feasibility

  Life Edit accelerates genomic medicine by comparing five editing modalities, engineering new enzymes, and rapidly pinpointing optimal strategies that boost feasibility, cut risk, and speed clinical progress.

• Regulatory Brief: USP 382 Updates

  As regulations continue to shift, staying current with the latest expectations is essential for maintaining compliance and ensuring patient safety.

• FDA's 483 Playbook: What It Means For Pharma Outsourcing — And What It Doesn't Address

  For those involved in outsourcing, the new FDA draft guidance regarding FDA Form 483 observations reshapes the accountability framework. The public comment period ends May 8.

• Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables

  A new draft guidance document from ICH, issued jointly with the EMA, adopts the position that the assessment of leachables and extractables requires a holistic framework for risk evaluation.

• How Drugs Are Manufactured And Administered

  Modern medicine includes far more than familiar over‑the‑counter products. Explore how drug composition, formulation, and administration work together to shape today’s therapies.

• How To Select The Right Fill-Finish CDMO For Phase I–II

  Early‑phase programs require flexible, technically aligned fill‑finish partners. Mid‑sized CDMOs offer a balance of agility, infrastructure, and regulatory maturity suited to Phase I–II needs.

• Pharma's Guide To Navigating Complex Impurity Compliance And Profiling

  Evolving regulations require proactive impurity control using trace‑level detection, solid risk assessment, advanced analytics, and ongoing monitoring to prevent compliance issues.